linjc16/ctgov huggingface dataset:
Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography

Study Overview
=================
Brief Summary
-----------------
This study examines the effect of vitamin D on Retinal changes in patient with optic Neuritis.

Official Title
-----------------
The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography

Conditions
-----------------
Optic Neuritis

Intervention / Treatment
-----------------
* Drug: Vitamin D
* Drug: Vitamin D withheld


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 15-50 years no history of demyelinative events level of vitamin d below 20 ng/ml no pass 10-32 day from starting symptom Exclusion Criteria: using vitamin D supplement

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: vitamin D<br>vitamin d 50000/w | Drug: Vitamin D<br>* vitamin D ,50000 unit /week<br>|
| Sham Comparator: control<br>follow up | Drug: Vitamin D withheld<br>* do not receive anything<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement Retinal nerve fiber layer (RNFL) thickness by OCT |  | 10-32 days after optic neuritis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement RNFL thickness by OCT |  | 6 months after optic neuritis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin d
House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance

Study Overview
=================
Brief Summary
-----------------
In this project, PBMCs will be isolated from HDM allergic and non allergic patient and then stimulated with HDM crude extract. The expression of inflammasome and the correlation of inflammasome activation and steroid resistance will be investigated.

Official Title
-----------------
Effects and Mechanism of House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance

Conditions
-----------------
Allergic Asthma

Intervention / Treatment
-----------------
* Biological: House dust mite


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HDM allergic and non allergic subjects Exclusion Criteria: Pregnant subject, cancer

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Steroid resistance in HDM allergic patients<br> | Biological: House dust mite<br>* As a stimulant to induce inflammasome activation<br>|
| Experimental: Steroid resistance in non HDM allergic subjects<br> | Biological: House dust mite<br>* As a stimulant to induce inflammasome activation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inflammasome activation by HDM | The expression of NLRP3 in PBMCs will be measured by western blot after HDM stimulation. | 6 hours | 
| Steroid receptor phosphorylation by HDM | The expression of steroid receptor will be detected by western blot and real-time PCR after HDM stimulation. | 6 hours |
To Identify Potential New Urine Marker Panel for Cancer Screening

Study Overview
=================
Brief Summary
-----------------
Polyamines are naturally produced metabolites in our cells. There were some reports suggested the urinary levels of polyamines were altered in patients with different cancers. This study is to explore the use of urinary polyamine for the diagnosis of common cancers.

Detailed Description
-----------------
Urine tests is a simple, non-invasive approach for cancer detection. One example of such cancer biomarkers are natural polyamines. Recently, there are also other reports on the use of polyamines in diagnosis of other cancers. In this larger scale study, with inclusion of subjects with different cancer types, to further assess the correlation urine polyamines and other urine metabolite markers for the diagnosis of different cancer types and investigate their role as a potential non-invasive marker for cancer detection and monitoring.

Official Title
-----------------
To Identify Potential New Urine Marker Panel for Cancer Screening

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with age > 18 years old. For cancer patients, a histological diagnosis of cancer is available. For normal control, there is no diagnosis of cancer in the medical record. Exclusion Criteria: Patient with recent urinary tract infection within 6 weeks prior to urine collection. Patient with recent urethral instrumentation, such as Foley catheter insertion, cystoscopy etc, within 6 weeks prior to urine collection. Patient refused or unable to provide consent for the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The sensitivity and specificity of cancer detection by urine polyamines | Urine samples will be prepared and analyzed by ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometer (UPLC-MS/MS). Receiver operating characteristics (ROC) curve for overall and individual cancer diagnosis will be performed.pathological result will be assessed. | 1 month after surgery |
Clinical Reminders in Test Reports to Improve Guideline Compliance

Study Overview
=================
Brief Summary
-----------------
Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.

Detailed Description
-----------------
Background: Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal. Objectives: To determine if a reminder attached to the echocardiography report would increase the use of beta-blockers among patients with depressed left ventricular function. Methods: We are randomizing consecutive patients undergoing echocardiography at one of three VA echocardiography laboratories with reduced left ventricular ejection fraction (<40%) and no echocardiographic contraindication to beta-blockers (e.g. aortic stenosis) to a reminder for use of beta-blockers or to no reminder. The reminder gives starting doses for two commonly used beta-blockers (carvedilol and metoprolol). Patients are excluded from the analysis if they leave the health care system or die within three months of randomization. The primary outcome is a prescription for a beta-blocker between three and nine months following echocardiography Status: The project is complete.

Official Title
-----------------
Clinical Reminders in Test Reports to Improve Guideline Compliance

Conditions
-----------------
Heart Failure, Congestive

Intervention / Treatment
-----------------
* Behavioral: Clinical Reminder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Those undergoing echocardiography at one of the participating laboratories with an ejection fraction < 45%. Exclusion Criteria: aortic stenosis, mitral stenosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Arm 1<br> | Behavioral: Clinical Reminder<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prescription for any beta-blocker |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prescription for carvedilol or metoprolol succinate |  |  |
Complications From Left Atrial Appendage Occluder

Study Overview
=================
Brief Summary
-----------------
The following case reported a rare complication of left atrial appendage perforation complicated by cardiac tamponade during LAAO device deployment and its corresponding surgical management

Official Title
-----------------
The Management of Left Atrial Appendage Perforation Complicated by Cardiac Tamponade During Left Atrial Appendage Occluder Device Deployment

Conditions
-----------------
Atrial Fibrillation, Cardiac Perforation, Cardiac Tamponade

Intervention / Treatment
-----------------
* Procedure: Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 73-year-old woman with CHA2DS2-VASc score 4 Exclusion Criteria: nil
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Surgery|Sutured by Prolene 3-0 with two layers of pledge|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment related adverse events |  | Three months |
DE-111 Against Timolol Ophthalmic Solution 0.5%

Study Overview
=================
Brief Summary
-----------------
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a multicenter, randomized, double-masked, parallel-group comparison study. Safety will be compared and evaluated as well.

Official Title
-----------------
A Double-masked Study of DE-111 Ophthalmic Solution Versus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension - Phase 3, Confirmatory Study -

Conditions
-----------------
Open Angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: DE-111 ophthalmic solution
* Drug: Timolol ophthalmic solution 0.5%
* Drug: Placebo ophthalmic solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with primary open angle glaucoma or ocular hypertension Provided signed, written informed consent 20 years of age and older If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study Exclusion Criteria: Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception Presence of any abnormality or significant illness that could be expected to interfere with the study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DE-111 ophthalmic solution<br>DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes. | Drug: DE-111 ophthalmic solution<br> <br> Drug: Placebo ophthalmic solution<br> <br> |
| Active Comparator: Timolol ophthalmic solution 0.5%<br>Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes. | Drug: Timolol ophthalmic solution 0.5%<br> <br> Drug: Placebo ophthalmic solution<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Mean Diurnal IOP (Intraocular Pressure) at End of Study | Mean diurnal IOP (intraocular pressure) was calculated as an average of IOP (intraocular pressure) at 9:30 (pre-dose), 11:30 and 17:30. | Week 0(Baseline) and Week 4(End of Study) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary open angle glaucoma or ocular hypertension
Microbiotic Analysis in Digestive Endocrine Tumors

Study Overview
=================
Brief Summary
-----------------
Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. This prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor. Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.

Official Title
-----------------
Microbiotic Analysis in Digestive Endocrine Tumors

Conditions
-----------------
Digestive Neuroendocrine Tumor, Fecal Microbiota, Bacterial Signature

Intervention / Treatment
-----------------
* Biological: Biological sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old or older naive patient with digestive neuroendocrine tumor (pancreas (cytology or histology per endoscopy or on surgical specimen) or small intestine), secreting or not, initiating a extended release Lanreotide treatment registered with a social security scheme Exclusion Criteria: medical contraindication to somatostatine analogs use history of extended release somatostatine analogs treatment antibiotic use or colonoscopic purge in the last 3 weeks preceding fecal sample pregnant or breastfeeding women person requiring tutorship, guardianship, or person legally protected

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with digestive neuroendocrine tumor<br>naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment | Biological: Biological sampling<br>* Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing<br>|
| Patient without tumor<br>Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacterial genomic signature | bacterial genomic signature by fecal ARN16S analysis at enrollment | Baseline visit |
Neurocognitive Enhancement in Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the effects of neurocognitive enhancement on cognitive abilities and related social and adaptive behaviours in individuals diagnosed with major depressive disorder. Subjects in this study will be randomized to receive Neurocognitive Enhancement Therapy (NET) or to a wait list and then NET . Secondary aims include examining whether the cognitive benefits are potentiated by repeated exposure during in-home practice with complementary exercises. Additionally, the investigators will examine the durability of the effects and their generalization to functional capacity and everyday functional performance after completion of the groups.

Official Title
-----------------
Neurocognitive Enhancement in Major Depressive Disorder

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Behavioral: Neurocognitive Enhancement
* Behavioral: Wait List


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female. Subjects will be between the ages of 18 and 65, which is the age range with available normative comparison data. Exclusion Criteria: Presence of a medical diagnosis that is associated with known cognitive impairments, such as multiple sclerosis, cerebrovascular accident, dementia, or history of traumatic brain injury. Subjects with a reading level below grade 6, as assessed with the Wide Range Achievement Test - Reading Recognition Subtest, will be excluded because of the likelihood of not understanding task instructions. Subjects with uncorrectable vision or hearing impairment that would preclude valid assessments or intervention procedures.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neurocognitive Enhancement<br>neurocongnitive enhancement | Behavioral: Neurocognitive Enhancement<br>* Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.<br>|
| Other: Wait List<br>no intervention | Behavioral: Wait List<br>* Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance |  | 20 weeks |
Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare alfuzosin GITS once daily versus placebo in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.

Official Title
-----------------
Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo on the Successful Rate of Trial Without Catheter in Patients With Acute Urinary Retention With Long Term Follow up

Conditions
-----------------
Prostatic Hyperplasia, Urinary Retention, Acute Disease

Intervention / Treatment
-----------------
* Drug: Alfuzosin GITS (Xatral XL)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 50 or above Admitted for AUR due to BPH with PVR of 500 ml or more Exclusion Criteria: Previous history of TURP Use of alpha blockers within recent 8 months Renal impairment (serum creatinine >140 umol/l) Poor premorbid state

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Alfuzosin GITS (Xatral XL)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful rate of Trial Without Catheter (TWOC) at phase 1 |  | At discharge after TWOC (at the end phase one) | 
| Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1 |  | From the end of phase one to eight months after successful TWOC (the end of phase 2) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOC |  | From the time of treatment drug administration to the end of phase 1 | 
| Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR) |  | At the end of phase I (discharge after TWOC) and at the end of phase 2 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Benign Prostatic Hyperplasia (BPH), Acute Retention of Urine (AUR)